Neurocrine Biosciences Inc 8-K Filing
Ticker: NBIX · Form: 8-K · Filed: Nov 24, 2025 · CIK: 914475
| Field | Detail |
|---|---|
| Company | Neurocrine Biosciences Inc (NBIX) |
| Form Type | 8-K |
| Filed Date | Nov 24, 2025 |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Neurocrine Biosciences Inc (ticker: NBIX) to the SEC on Nov 24, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.001 (nge on which registered Common Stock, $0.001 par value NBIX Nasdaq Global Select Mar).
How long is this filing?
Neurocrine Biosciences Inc's 8-K filing is 2 pages with approximately 551 words. Estimated reading time is 2 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 551 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2025-11-24 16:02:50
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value NBIX Nasdaq Global Select Mar
Filing Documents
- nbix-20251121.htm (8-K) — 23KB
- exhibit101.htm (EX-10.1) — 9KB
- exhibit101001.jpg (GRAPHIC) — 211KB
- exhibit101002.jpg (GRAPHIC) — 238KB
- exhibit101003.jpg (GRAPHIC) — 117KB
- exhibit101004.jpg (GRAPHIC) — 45KB
- nbix-20251121_g1.jpg (GRAPHIC) — 18KB
- 0000914475-25-000186.txt ( ) — 1038KB
- nbix-20251121.xsd (EX-101.SCH) — 2KB
- nbix-20251121_lab.xml (EX-101.LAB) — 21KB
- nbix-20251121_pre.xml (EX-101.PRE) — 12KB
- nbix-20251121_htm.xml (XML) — 3KB
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Amendment to Amended and Restated Employment Agreement dated November 21, 2025 between the Company and Eiry W. Roberts, M.D. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NEUROCRINE BIOSCIENCES, INC. Dated: November 24, 2025 /s/ Darin M. Lippoldt Darin M. Lippoldt Chief Legal Officer